SynAct Pharma Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de SynAct Pharma han disminuido a una tasa media anual de -47.4%, mientras que en la industria Biotechs los beneficios crecieron en un 17.7% anualmente.

Información clave

-47.4%

Tasa de crecimiento de los beneficios

-32.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	0.7%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera	-122.5%
Margen neto	n/a
Próxima actualización de resultados	31 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation

Sep 04

Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?

Jan 18

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

Sep 03

SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans

Apr 07

Companies Like SynAct Pharma (NGM:SYNACT) Are In A Position To Invest In Growth

Dec 23

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero SynAct Pharma. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

OM:SYNACT Ingresos, gastos y beneficios (SEK Millions)
Fecha	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	-216	34	105
30 Sep 23	-156	33	116
30 Jun 23	-148	29	115
31 Mar 23	-129	27	100
31 Dec 22	-99	36	70
30 Sep 22	-95	33	69
30 Jun 22	-89	31	64
31 Mar 22	-78	22	63
31 Dec 21	-69	16	60
30 Sep 21	-52	15	46
30 Jun 21	-41	12	37
31 Mar 21	-35	10	29
31 Dec 20	-27	9	23
30 Sep 20	-29	-1	32
30 Jun 20	-24	1	25
31 Mar 20	-23	6	20
31 Dec 19	-24	10	15
30 Sep 19	-20	23	0
30 Jun 19	-23	26	0
31 Mar 19	-24	30	0
31 Dec 18	-23	6	22
30 Sep 18	-23	28	0
30 Jun 18	-19	23	0
31 Mar 18	-15	18	0
31 Dec 17	-15	18	0
30 Sep 17	-23	25	0
31 Dec 16	-21	22	0
31 Dec 15	-1	0	0

Ingresos de calidad: SYNACT actualmente no es rentable.

Margen de beneficios creciente: SYNACT actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: SYNACT no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 47.4% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de SYNACT en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: SYNACT no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.7%).

Rentabilidad financiera

Alta ROE: SYNACT tiene una rentabilidad financiera negativa (-122.49%), ya que actualmente no es rentable.

SynAct Pharma Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

SynAct Pharma AB to Report Q3, 2024 Results on Oct 30, 2024

SynAct Pharma AB to Report Q4, 2023 Results on Feb 23, 2024

SynAct Pharma AB to Report Q1, 2023 Results on May 05, 2023

Recent updates

SynAct Pharma AB has completed a Follow-on Equity Offering in the amount of SEK 49.239162 million.

New major risk - Revenue and earnings growth

Chief Operating Officer recently sold kr145k worth of stock

SynAct Pharma AB has filed a Follow-on Equity Offering in the amount of SEK 45 million.

SynAct Pharma AB Announces CEO Changes

SynAct Pharma AB Announces Outcomes of the Independent Audit of the 4-Week Resolve P2a Clinical Trial in Rheumatoid Arthritis

SynAct Pharma AB (publ) Announces Resignation of Marina Bozilenko as Member of the Board of Directors

New major risk - Financial position

SynAct Pharma AB to Report Q3, 2024 Results on Oct 30, 2024

SynAct Pharma Announces Additional Data from the Expand P2b Clinical Trial Supporting Continued Development of the Compound in Rheumatoid Arthritis

SynAct Pharma AB to Report Q4, 2023 Results on Feb 23, 2024

High number of new and inexperienced directors

Synact Pharma Appoints Kristen Harting as Chief Medical Officer, Effective 15 February 2024

Synact Pharma Expands Its Rheumatology Clinical Advisory Board with Three New Highly Experienced Advisors

SynAct Pharma AB, Annual General Meeting, May 23, 2024

SynAct Pharma AB has completed a Follow-on Equity Offering in the amount of SEK 60.525 million.

SynAct Pharma AB Announces Evaluation of the 4-Week RESOLVE P2a Clinical Trial in Moderate to Severe Active Rheumatoid Arthritis Patients with an incomplete Response to Methotrexate

SynAct Pharma AB Announces Additional Data from the Expands P2b Clinical Trial Further Supporting Efficacy and Activity seen in Patients with Elevated CRP

SynAct Pharma AB Announces Additional Data from the EXPAND P2b Clinical Trial and Identifies Population with Responsiveness to Resomelagon

Synact Pharma Announces Top Line Data from the 12-Week Expand P2b Clinical Trial in Severe Active Newly Diagnosed Rheumatoid Arthritis Patients

SynAct Pharma AB (Publ) Completes Dosing in Part A of Combined Phase 2A/B Resomelagon (AP1189) in Rheumatoid Arthritis (RA)

SynAct Pharma AB (publ) Completes Patient Recruitment for Part A of Combined Phase 2a/b RESOLVE Study of Resomelagon (AP1189) in Rheumatoid Arthritis

SynAct Pharma AB (publ) Announces the Completion of Dosing in the Phase 2b Expand Study of Resomelagon (AP1189) in Early Severe Rheumatoid Arthritis Patients

Chief Operating Officer recently bought kr78k worth of stock

SynAct Pharma AB Announces Appointment of Thomas Von Koch as Board Member

SynAct Pharma AB Appoints Björn Westberg as Chief Financial Officer

SynAct Pharma AB to Report Q1, 2023 Results on May 05, 2023

SynAct Pharma AB (OM:SYNACT) completed the acquisition of TXP Pharma AG from Boesen Biotech ApS, GL Capital AB, TJ Biotech Holding ApS, Quantass ApS, and James Knight.

SynAct Pharma AB Announces Change in Nomination Committee Prior to Agm 2023

Chief Operating Officer recently sold kr3.4m worth of stock

SynAct Pharma AB (OM:SYNACT) entered into a conditional agreement to acquire TXP Pharma AG from Boesen Biotech Aps, Glcapital Ab, TJ Biotech Holding ApS, Quantass ApS, and James Knight for approximately SEK 190 million.

No independent directors

SynAct Pharma AB Receives IND Clearance from the FDA for Phase 2A/B Trial of Ap1189 in Ra

SynAct Pharma AB, Annual General Meeting, May 25, 2023

Synact Submits Ind and Recruits First Patient

Synact Pharma Submits IND for US Phase 2A/B Clinical Trial

SynAct Pharma AB (Publ) Enrolls First Patient in Phase 2b Trial of Ap1189 in RA

SynAct Pharma AB Announces Approval of Amended Study Protocol for the Phase 2A Study in iMN

Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation

SynAct Pharma AB (publ) Announces That the Clinical Trial Application to Initiate the Clinical Phase 2B Study, Expand

SynAct Pharma AB Improves the Design of the Ongoing Phase 2A Study in Imn

SynAct Pharma AB Improves the Design of the Ongoing Phase 2A Study in Imn

Synact Pharma Receives pre-IND Response from the U.S. Food and Drug Administration

SynAct Pharma Submits CTA for Clinical Phase 2b Study in RA

John Haurum Declines Re-Election as Board Member of SynAct Pharma AB

SynAct Pharma AB Completes Clinical Pharmacokinetic Test of Ap1189 Tablet

No independent directors

Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?

SynAct Pharma AB Announces Additional Data from the BEGIN Study

SynAct Pharma AB Reports Positive PK Data on AP1189 Tablets

SynAct Pharma AB Completes Patient Recruitment to the Phase 2A Begin Study of Ap1189 in Early Severe Rheumatoid Arthritis

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

SynAct Pharma AB Provides an Update on Patient Recruitment in the Phase 2a Clinical Trial of AP1189 in Rheumatoid Arthritis

SynAct Pharma AB Announces Grant of Key European Patent Covering Ap1189

Chief Medical Officer Thierry Duvauchelle has left the company

Synact Pharma AB Announces Positive Data from A Phase 2A Trial of Ap1189 in Covid-19 Infected Patients

SynAct Pharma Files Patent Applications Related to AP1189 Derived APIs and Oral Formulations

SynAct Pharma Updates Phase II study with AP1189

Synact Pharma Expands Ap1189 Begin Study in Rheumatoid Arthritis Uk Version

SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans

SynAct Pharma AB Initiates Dosing in Part 2 of the Clinical Phase II Study with AP1189 in Covid-19 Infected Patients UK Version

Chief Financial Officer recently sold kr2.9m worth of stock

SynAct Pharma AB Names James Knight as Chief Business Officer

New 90-day high: kr61.00

SynAct Pharma AB Names Thomas Boesen as Chief Operating Officer

New 90-day high: kr51.00

Companies Like SynAct Pharma (NGM:SYNACT) Are In A Position To Invest In Growth

New 90-day low: kr34.20

Synact Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis

SynAct Pharma Completes Part 1 of Clinical Phase II Study with AP1189 in Rheumatoid Arthritis

New 90-day high: kr46.30

SynAct Pharma Initiates Phase II Study with AP1189 for the Treatment of ARDS in COVID-19 Patients

Desglose de ingresos y gastos
Beta